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Ascorbic acid improves embryonic cardiomyoblast cell survival
and promotes vascularization in potential myocardial grafts in
vivo
Abstract
Organ restoration via cell therapy and tissue transplantation is limited by impaired graft survival. We
tested the hypothesis that ascorbic acid (AA) reduces cell death in myocardial grafts both in vitro and in
vivo and introduced a new model of autologous graft vascularization for later transplantation. Luciferase
(Fluc)- and green fluorescent protein (GFP)-expressing H9C2 cardiomyoblasts were seeded in gelatin
scaffolds to form myocardial artificial grafts (MAGs). MAGs were supplemented with AA (5 or 50
mumol/L) or plain growth medium. Bioluminescence imaging showed increased cell photon emission
from day 1 to 5 in grafts supplemented with 5 mumol/L (p < 0.001) and 50 mumol/L (p < 0.01) AA. The
amount of apoptotic cells in plain MAGs was significantly higher than in AA-enriched grafts. In our in
vitro model, AA also enhanced H9C2 cell myogenic differentiation. For in vivo studies, MAGs
containing H9C2-GFP-Fluc cells and enriched with AA (n = 10) or phosphate-buffered saline (n = 10)
were implanted in the renal pouch of Wistar rats. At day 6, postimplantation bioluminescence signals
decreased by 74% of baseline in plain MAGs versus 36% in AA-enriched MAGs (p < 0.0001). AA
grafts contained significantly higher amounts of blood vessels, GFP(+) donor cells, and endothelial
cells. In this study, we identified AA as a potent supplement that improves cardiomyoblast survival and
promotes neovascularization in bioartificial grafts.
Ascorbic Acid Improves Embryonic Cardiomyoblast
Cell Survival and Promotes Vascularization
in Potential Myocardial Grafts In Vivo
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Organ restoration via cell therapy and tissue transplantation is limited by impaired graft survival. We tested the
hypothesis that ascorbic acid (AA) reduces cell death in myocardial grafts both in vitro and in vivo and intro-
duced a new model of autologous graft vascularization for later transplantation. Luciferase (Fluc)- and green
fluorescent protein (GFP)-expressing H9C2 cardiomyoblasts were seeded in gelatin scaffolds to form myocardial
artificial grafts (MAGs). MAGs were supplemented with AA (5 or 50 mmol=L) or plain growth medium. Bio-
luminescence imaging showed increased cell photon emission from day 1 to 5 in grafts supplemented with
5 mmol=L ( p< 0.001) and 50 mmol=L ( p< 0.01) AA. The amount of apoptotic cells in plain MAGs was signifi-
cantly higher than in AA-enriched grafts. In our in vitro model, AA also enhanced H9C2 cell myogenic differ-
entiation. For in vivo studies, MAGs containing H9C2-GFP-Fluc cells and enriched with AA (n¼ 10) or
phosphate-buffered saline (n¼ 10) were implanted in the renal pouch of Wistar rats. At day 6, postimplantation
bioluminescence signals decreased by 74% of baseline in plain MAGs versus 36% in AA-enriched MAGs
( p< 0.0001). AA grafts contained significantly higher amounts of blood vessels, GFPþ donor cells, and endo-
thelial cells. In this study, we identified AA as a potent supplement that improves cardiomyoblast survival and
promotes neovascularization in bioartificial grafts.
Introduction
The fabrication of sufficiently thick three-dimensional(3D) myocardial grafts by means of tissue engineering is
limited by impaired cell viability in unperfused in vitro sys-
tems.1 Further, cell death constitutes a major drawback when
attempts are made to restore heart muscle via cell or bioar-
tificial tissue implantation.2–4 Following transplantation, cells
in 3D grafts will be challenged by proapoptotic stimuli and an
intense inflammatory response arising from the surrounding
ischemic tissue,5,6 as well as by hypoxia, particularly in the
core of the bioengineered graft.7 Besides donor cell survival,
functional integration and engraftment of bioengineered
tissues in the recipient organism are equally critical for a
successful myocardial restoration. It has been reported that
neovascularization within myocardial grafts plays a key role
for both cardiomyocyte survival and organization.8 All to-
gether highlights the paramount importance of blood supply
in myocardial grafts for heart repair.
Given the relevance of hypoxia and oxidative stress for the
fate of cardiac cells after ischemic injury as well as within
thick bioengineered tissues, we postulate that ascorbic acid
(AA) is a factor that might reduce cell death in myocardial
grafts both in vitro and in vivo. This hydrophilic antioxidant
scavenges toxic free radicals and other reactive oxygen spe-
cies efficiently.9 Further, attenuation of hypoxia-induced
apoptosis after AA treatment in vitro has been demonstrated
in HL-1 cardiomyocytes10 and endothelial progenitor cells.11
AA also exerts a stimulatory effect on angiogenesis through
increase of collagen type IV synthesis by endothelial cells.12
It has been shown that human umbilical vein endothelial cell
type IV collagen production is enhanced when AA is added
in vitro. At physiological concentrations (up to 100mmol=L),
AA induces tube formation by human umbilical vein endo-
thelial cells in cultured extracellular matrix.12 Further, large
doses of AA induce superior mesenchymal tissue healing in
rats, because of early angiogenesis induction and increased
collagen synthesis.13 Finally, AA is available ubiquitously, is
an essential part of our diet at a global scale, and can be
easily administered in large doses as a therapeutic supple-
ment in various formulations. However, the potential of AA
for cell therapy and tissue repair has not been exploited yet.
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Experimental studies to assess the effect of AA on cell sur-
vival in 3D compounds destined for myocardial restoration
have yet to be conducted.
Accordingly, the aim of our study was to investigate
whether bioartificial grafts (scaffold–cell compounds) for
myocardial repair, which have been enriched with AA, dis-
play improved donor cell viability, both in vitro and in vivo.
In addition, we assess whether such enrichment would have
any effect on angiogenesis and remodeling of thick bioarti-
ficial tissues, suitable for implantation and myocardial re-
pair. To examine our hypothesis, a novel renal pouch model
for in vivo prevascularization of 3D tissue grafts was devel-
oped in healthy rats.
Materials and Methods
Cell culture
H9C2(2-1) cardiomyoblasts derived from embryonic rat
hearts were obtained from the American Type Culture Col-
lection (Manassas, VA) and maintained in Dulbecco’s modi-
fied Eagle medium (DMEM) supplemented with 10% fetal
bovine serum, 100,000U=L of penicillin, and 100mg=L of
streptomycin (GIBCO, Invitrogen Corporation, Carlsbad,
CA), under 5% CO2 at 378C. Cells were subcultured on reach-
ing subconfluency to maintain the myoblast phenotype.
Generation of fluorescent=bioluminescent cell lines
pWPT-GFP (kindly provided by Dr. D. Trono; University of
Geneva, Geneva, Switzerland) and pWPT-Fluc (modified from
pWPT-GFP) lentiviral vectors were used to infect H9C2 cells.
pWPT-Fluc was cloned by removing green fluorescent protein
(GFP) from pWPT-GFP and inserting the firefly luciferase
(Fluc) gene PCRed from pGL3 (Promega, Madison, WI).
Lentiviral vectors were produced by transient transfection of
293T cells. About 5106 cells=plate were seeded in 10-cm
tissue culture plates at 24h before transfection. The latter was
performed using calcium phosphate precipitation method
with 10mg pWPT-GFP or pWPT-Fluc vector, 7.5mg helper
plasmid pCMV8.91, and 2.5mg of MD2G envelope plasmids
(gifts from Dr. D. Trono, University of Geneva, Geneva,
Switzerland). Cells were replaced with fresh medium at 14–
16h after transfection. The supernatant was filtered through a
0.45-mm filter, and the titer of supernatant on 293T cells was
determined using flow cytometry. H9C2 cells were shown to
be highly infectable (>90%) with unconcentrated lentiviral
supernatant (unpublished data). H9C2 cells to be used in vivo
were initially infected with supernatant containing pWPT-
GFP, sorted for GFP positivity, and subsequently infected with
pWPT-Fluc (H9C2-GFP-Fluc). Further, cells destined to in vitro
experiments were infected with pWPT-Fluc (H9C2-Fluc).
3D graft preparation for in vitro studies
Prior to these experiments, AA concentrations without cy-
totoxic effect on H9C2 cells were established in our laboratory
(data not shown) and have also been previously described in
other cell types.12,14 Sterile, porous sponges prepared from
purified porcine skin gelatin (Gelfoam; Pharmacia & Upjohn
Company, Kalamazoo, MI) were used as scaffold material to
fabricate 3D myocardial artificial grafts (MAGs). Gelfoam
squares (10105mm) were placed in eight-well chamber
slides (Lab-TekII Chamber Slide; NUNC A=S, Roskilde,
Denmark) under sterile conditions. Subsequently, foams were
hydrated with 100mL growth medium supplemented with 5
or 50mmol=L L-AA (Sigma, St. Louis, MO). Scaffolds with just
medium, that is, without AA and=or without cells, were used
as controls. A 100mL medium solution containing 2.5105
H9C2-Fluc cells was added on top of the 3D scaffolds.
Chamber slides were then placed in an incubator under 5%
CO2 at 378C for 30min to allow cell solution absorption into
the sponge. Next, scaffolds were covered with 0.4mL growth
medium, placed back into the incubator, and the mediumwas
exchanged daily. Assays were conducted in quadruplet in five
separate experiments.
In vitro bioluminescence imaging
Bioluminescence imaging (BLI) was used to evaluate the
effect of AA on H9C2-Fluc cells in vitro survival when
seeded in 3D MAGs after 1, 3, and 5 days in culture (n¼ 20=
treatment=time point). For BLI, 150mg=mL working solution
of d-luciferin (Caliper Life Sciences, Hopkinton, MA) in
prewarmed cell culture medium was added to each well and
the chamber slides were scanned after 5min using a Xenogen
IVIS Lumina System (Caliper Life Sciences). Biolumines-
cence was quantified in units of photons per second total flux
(p=s), using Living Imaging Software version 2.6 (Caliper
Life Sciences).
dUTP nick-end labeling assay
and immunohistochemical staining
for active caspase 3
Three-dimensional MAGs were fixed in 10% buffered for-
malin, embedded in optimal cutting temperature (OCT)
compound (Tissue-Tek, Sakura Finetek, Tokyo, Japan), and
stored at 808C after in vitro experiments at days 3 and 5.
In situ terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) analysis was done using the
ApopTag Red In Situ Apoptosis Detection Kit (Millipore,
Billerica, MA), according to the manufacturer’s instructions,
on 5-mmcryosections. The sections from at least three different
experiments were visualized using a Leica TCS SP5, DMI6000
confocal laser scanning microscope (Leica Microsystems,
Wetzlar, Germany). The number of TUNEL-positive cells was
counted in 10 different fields (400), from three different
grafts=treatment. Next, to quantify apoptosis and exclude
necrosis, 10-mm cryosections were stained with active caspase
3 antibody (1:100, rabbit polyclonal antibody to active caspase
3, ab2302;Abcam,Cambridge, UnitedKingdom). The sections
were counterstained with 40,6-diamidino-2-phenylindole
(DAPI) (Molecular Probes, Invitrogen, Carlsbad, CA) and
z-stacks in 0.5 mm steps were obtained using confocal micros-
copy. A single image of maximum projection was obtained
from the z-stacks by using Leica Application Suite Advanced
Fluorescence quantification software (version 1.8.2, build
1465). The sections from at least three different experi-
ments were analyzed. Cells were counted using Image J 1.42q
(National Institutes of Health, Bethesda, MD). The percent-
age of TUNEL-positive and active caspase 3-positive cells was
calculated as follows: 100(number of positive cells counted=
total number of nuclei counted).
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Assessment of H9C2 phenotype in 3D culture
Immunohistochemical assays were carried out to evaluate
the effect of AA on H9C2 cardiomyoblast differentiation.
Five-micrometer cryosections obtained from in vitro experi-
ments at days 3 and 5 were stained with an antibody specific
to a-cardiac and skeletal (sarcomeric) muscle actins (1:100,
monoclonal mouse anti-sarcomeric actin, clone Alpha-Sr-1;
DakoCytomatation, Glostrup, Denmark). The sections were
then incubated with a secondary antibody Alexa Fluor-568,
counterstained with DAPI (Molecular Probes, Invitrogen,
Carlsbad, CA), and visualized with an Olympus BX61 fluo-
rescence microscope equipped with a DP72 12.8 megapixel
cooled digital camera (Olympus, Tokyo, Japan). Photomicro-
graphs were processed using the DP2-BSW 2.2 (build 6212)
software (Olympus).
Animals and renal pouch model
This study conforms with the Guide for the Care and Use
of Laboratory Animals published by the U.S. National In-
stitutes of Health (NIH publication no. 85-23, revised 1996).
The experimental protocol was approved by the National
University of Singapore—Institutional Animal Care and Use
Committee. Male SPF Wistar rats (300–350 g) were used for
our experiments. All surgical procedures were performed
using aseptic techniques.
Anesthesia was induced and maintained in animals by
inhalational isoflurane (2%) and intraperitoneal injection of
ketamine:xylazine (90mg=kg:10mg=kg). Carprofen (5mg=kg,
subcutaneous [SC]) was administered preoperatively for an-
algesia. A midlaparotomy was performed, followed by dis-
placement of the bowel and mild retraction of the kidney.
Blunt preparation of the retroperitoneal fossa was done and a
pouch was created between the retrorenal fat and the psoas
muscle. Subsequently, the MAG was implanted into the retro-
renal pouch. Grafts containing cells were implanted in the
right renal pouch, whereas acellular controls were implanted
in the contralateral pouch. We did not use suture material in
the implantation process. Finally, the bowel was repositioned
and the abdomen was closed in two layers. The animals were
allowed to recover in a small-animal ICU. Carprofen (5mg=
kg=day, SC) was administered postoperatively for analgesia.
3D graft preparation for in vivo studies
Eight rats were used to test several 3D matrices and to
identify the one displaying the least degradation and low
inflammatory reaction after 10 days of implantation using
the renal pouch model. Four different collagenous foam-
scaffolds from diverse origin (i.e., equine collagen and hu-
man fibrinogen [Tachotop; Nycomed, Zurich, Switzerland],
bovine collagen [Lyostypt; B. Braun Melsungen AG, Mel-
sungen, Germany], native equine collagen [TissuFleece E;
Baxter, Vienna, Austria], and porcine skin gelatin [Gelfoam])
were implanted in the renal pouch without cells (data not
shown). The porcine gelatin foam was recovered almost in-
tact after 10 days of implantation, and hence, it was chosen
for the cell-based animal experiments.
H9C2-GFP-Fluc cells were washed three times in cold
phosphate-buffered saline (PBS) and centrifuged. Gelfoam
squares (20205mm) were placed in 12-well plates and
covered with 4106 H9C2-GFP-Fluc cells in 250 mL PBS
under sterile conditions. Based on our in vitro studies, we
chose 5mmol=L L-AA in PBS enrichment for the AA animal
group (group A, n¼ 10). Plain MAGs without AA (PBS and
cells) were used as control group (group B, n¼ 10). Acellular
grafts containing just PBS (group C, n¼ 10) or 5mmol=L AA
in PBS (group D, n¼ 10) were used as negative controls and
implanted in the left renal pouch.
In vivo BLI
We performed optical in vivo BLI with the Xenogen-IVIS
Lumina in vivo imaging system as previously described.15–17
Briefly, rats were anesthetized with 2% isoflurane, and
d-luciferin was administered intraperitoneally at a dose of
150mg=kg of body weight. They were placed in the chamber
in supine position and peak luciferase activity was detected
by imaging the animals for 40min with 2-min acquisition
separated by 2-min intervals.17 The same rats were scanned
repeatedly postimplantation at days 1, 3, and 6. Regions of
interest indicating the locations of most intense signals were
created using Living Imaging Software version 2.6. Biolu-
minescence was quantified in units of photons per second
total flux (p=s).15,18
Immunohistochemistry—Assessment of GFP
and rat endothelial cell antibody expression
At 7 days postimplantation, MAGs were explanted and
fixed in 10% formalin. The grafts were subsequently optimal
cutting temperature (OCT) compound embedded and stored
at 808C. Immunohistochemical staining was performed in
5-mm cryosections using the primary antibody rat endothelial
cell antibody-1 (RECA-1), a ubiquitous marker of rat endo-
thelial cells (1:50 monoclonal mouse anti-RECA-1; HyCult
Biotechnology b.v., The Netherlands). The sections were then
incubated with secondary antibodies Alexa Fluor-647 and
Anti GFP-Alexa Fluor-488, and nuclei were stained with
DAPI (Molecular Probes).
Images were acquired using a Leica TCS SP5, DMI6000
confocal laser scanning microscope (Leica Microsystems),
with 40 and 20magnifications. They were subsequently
processed using Leica Application Suite Advanced Fluores-
cence quantification software (version 1.8.2, build 1465).
The mean pixel intensity, a semiquantitative analysis of
fluorescence, was used to evaluate GFP and RECA expres-
sion within the explanted 3D grafts. Predefined settings for
laser power and detector gain were used for all experiments.
Histological analysis
We performed Masson’s trichrome and hematoxylin–
eosin staining on 5-mmsections of formalin-fixed and paraffin-
embedded explanted MAGs. Histological assessment was
performed by an experienced pathologist in a blinded fash-
ion. To assess angiogenesis within the explanted graft, the
number of blood vessels per high-power field (hpf ) (400)
was quantified. The degree of cell infiltration and fibrosis
was evaluated as the percentage of area of the scaffold infil-
trated by cellular reaction and collagen deposition covering
the total cellular reaction, using a manual semiquantitative
method. Ten random fields were chosen in each section for all
the quantifications.
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Statistical analysis
Data are presented as mean standard deviation. To test
for statistically significant differences, we used two-way
analysis of variance and the unpaired Student’s t-test when
appropriate. Differences were considered significant if p<
0.05. Regression plots were used to describe the relationship
between bioluminescence and cell number in vitro; r2-values
were reported to assess the quality of the linear regression
model. All the statistical analyses were performed using
GraphPad Prism software version 5.01 for Windows
(GraphPad Software, San Diego, CA).
Results
In vitro BLI=effect of AA on 3D H9C2
cell graft survival in vitro
BLI showed that there was a significant increase in cell
bioluminescent baseline signals from day 1 to 5 in grafts
supplemented with both 5 and 50 mmol=L AA (55.23%
0.45%, p< 0.001 and 49.83% 0.45%, p< 0.01, respectively;
Fig. 1A–D). H9C2-Fluc cells seeded within the 3D MAGs
receiving 5 mmol=L AA-supplemented medium showed sig-
nificantly larger bioluminescent signals after 3 days
(2.1108 9.5107 p=s vs. 1.5108 7.4107 p=s, p< 0.05 vs.
control) and 5 days in culture (2.3108 7.9107 vs.
1.7108 4.8107, p< 0.05 vs. control). Likewise, 50mmol=L
AA-supplemented grafts displayed significantly increased
cell signals at day 5 when compared with control grafts re-
ceiving plain culture medium (2.0108 8.0107, p< 0.05 vs.
control; Fig. 1D). There were no large differences in photon
emission between the two dosages of AA.
Histological cell counts (DAPIþ cells) indicated that the
amount of DAPIþ cells per hpf (400) in the 5mmol=L AA-
enriched grafts was significantly higher than in the plain
grafts after 3 days in culture (53 21.4 vs. 30 7.18, p< 0.05).
Likewise, mean cell number was higher in grafts that received
50mmol=L AA after 5 days in static culture when compared
with untreated MAGs (41.4 14.3 vs. 19.6 6.9, p< 0.05).
There were differences in cell density between the AA-treated
grafts. A good correlation of luciferase activity per graft to
mean cell number (DAPIþ cells=graft) was found after 3 days
(r2¼ 0.90) and 5 days (r2¼ 0.97) in culture (Fig. 1E, F).
The effect of AA on cell apoptosis in 3D myocardial
bioartificial grafts in vitro
TUNEL assay and active caspase 3 staining were used to
assess the effect of AA on H9C2-Fluc cells apoptosis when
cultured in thick 3D MAGs (Fig. 2A–F). The percentage of
TUNELþ cells per hpf (400) in plain grafts increased sig-
nificantly from day 3 in culture (23.5% 12.6%) to day 5
(61.9% 30.1%, p< 0.001). The percentage of TUNELþ cells
was significantly inferior in the 5 and 50mmol=L MAGs at
day 5 in culture (4.8% 8.6%, p< 0.001 and 8.3% 9.2%,
p< 0.001, respectively) when compared with plain control
grafts (61.9% 30.1%) (Fig. 2G). Given that TUNEL assay
tags apoptotic and necrotic cells, we used active caspase 3
staining as a more specific method to identify apoptotic cells.
The percentage of active caspase 3þ cells was considerably
higher in plain grafts after 3 days (41.6% 11.2%) and 5 days
(44.8% 20.0%) in culture when compared with both dos-
ages of AA (Fig. 2A–F, H). The 5mmol=L AA grafts had
16.5% 6.17% ( p< 0.01) apoptotic cells at day 3 and
15.7% 6.8% ( p< 0.001) at day 5. Likewise, the 50 mmol=L
AA MAGs had 11% 5.7% ( p< 0.01) of apoptotic cells at
day 3 and 18.8% 5.9% ( p< 0.01) at day 5 in culture.
AA effect on H9C2 cells phenotype in vitro
After 3 days in culture, H9C2 cardiomyoblasts were at-
tached to the scaffold material and formed a primitive syn-
cytium in all groups (Fig. 3A, C, E). Cells fused and formed
elongated myotube-like structures that were evident in the
AA-treated grafts (Fig. 3C, E). Immunohistochemical assays
revealed that a-sarcomeric actin was expressed by untreated
and AA-enriched cells after 3 and 5 days in 3D culture.
However, the AA-treated groups displayed organized sar-
comeric patterns at days 3 and 5 in culture, whereas z-lines
were not apparent in the untreated cells after 5 days in
culture (Fig. 3A–F).
In vivo BLI
Bioluminescent signals progressively decreased from day
1 to 6 in both the plain and AA-enriched MAGs (groups A
and B; Fig. 4A, B). However, photon emission fell dramati-
cally in plain MAGs (group B) from day 1 to 6 post-
implantation (Fig. 4A). Cell photon emission by day 6
plunged in a 74% 0.9% of the baseline in the plain MAGs,
whereas the AA-enriched graft signals decreased by just
36.42% 1.81% ( p< 0.0001). There was no significant dif-
ference in the mean photon emission among groups at days 1
and 3 postgraft implantation. However, the AA MAGs
(group A) displayed significantly higher cell signals at day 6
(6.1106 1.7105 p=s vs. 1.8106 2.8105 p=s, p< 0.05;
Fig. 4C).
Renal pouch model
None of the rats died before the scheduled euthanasia.
There were no visible signs of infection, inflammation, ad-
hesions, or foreign body reaction in any group after 1 week
of MAG implantation in the renal pouch. Explanted grafts
containing cells (groups A and B) displayed preserved size
and shape. In contrast, the negative control grafts (groups C
and D) were slightly smaller in size after 1 week of im-
plantation, which could be due to scaffold’s degradation. All
the implanted grafts were surrounded by a thin layer of
connective tissue adhered to the prerenal fat. Numerous
blood vessels were visible by the naked eye in both plain
(Fig. 5A) and AA-enriched MAGs (Fig. 5C), whereas fewer
vascular networks could be seen in acellular negative control
grafts (Fig. 5B, D).
Immunohistochemistry—Assessment of GFP
and RECA expression
Fluorescence pixel intensity analysis of the confocal mi-
crographs revealed that the amount of GFP-positive cells
(donor cells) was significantly greater in group A (AA-
enriched MAGs) when compared with the plain grafts from
group B (2.09 1.42 vs. 0.94 0.24, p< 0.01; Fig. 6E).
Abundant vascular networks infiltrating the MAGs could
be observed under the confocal microscope (Fig. 6A, B);
angiogenesis was particularly abundant in the AA group
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FIG. 1. In vitro BLI of 3D MAGs. BLI of AA-enriched and plain MAGs after (A) 1 day, (B) after 3 days in culture, and (C)
after 5 days in culture; n¼ 20. (D) MAGs receiving 50 and 5 mmol=L AA-supplemented medium showed significantly larger
bioluminescent signals after 5 days in culture ( p< 0.05 vs. control). 5mmol=L AA-enriched MAGs also displayed higher
photon emission at day 3 in culture ( p< 0.05 vs. control). An increase in cell bioluminescent baseline signals from day 1 to 5
was found in grafts supplemented with both 5 mmol=L AA (***p< 0.001) and 50 mmol=L AA (**p< 0.01). Correlation between
mean bioluminescence (mean total photon flux) and histological mean cell number after (E) 3 days and (F) 5 days in culture.
3D, three-dimensional; AA, ascorbic acid; BLI, bioluminescence imaging; hpf, high-power field (400); MAGs, myocardial
artificial grafts; SD, standard deviation.
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FIG. 2. Apoptosis assessment in 3D MAGs. Confocal micrographs of active caspase 3 staining (red) performed after 3 days
in culture in (A) plain MAGs, (B) 5 mmol=L AAMAGs, and (C) 50mmol=L AAMAGS. Active caspase 3 staining after 5 days in
culture in (D) plain MAGs, (E) 5 mmol=L AA MAGs, and (F) 50 mmol=L AA MAGS. The inset is a higher magnification
showing cytoplasmic active caspase 3 expression. (G) In the plain MAGs, TUNEL assay showed an increase in the percentage
of TUNEL-positive cells from day 3 to 5 in culture (***p< 0.001). (H) The percentage of apoptotic cells (active caspase 3þ) was
significantly inferior at days 3 and 5 in the 5 mmol=L AA ( p< 0.01 and p< 0.001, respectively) and 50mmol=L AA MAGs
( p< 0.01). Nuclei were counterstained with 40,6-diamidino-2-phenylindole (DAPI) (blue). Scaffold autofluorescence appears
in gray. Arrows pointing at some caspase 3-positive cells. Scale bars indicate 25 mm. TUNEL, dUTP nick-end labeling.
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(Fig. 6B, D). Further, blood vessel infiltration observed in
group A (AA) was not limited to the outmost regions of the
graft, as vessels in close contact with the gelatin scaffold
were found toward the graft’s core (Fig. 6D). Accordingly,
pixel intensity analysis showed that expression of the RECA
was significantly higher in the explanted grafts from group
A (AA) than those from group B (plain) (4.28 1.98 vs.
1.46 1.21, p< 0.05). Fluorescence intensity quantification
of DAPIþ cells did not reveal any difference among groups
(Fig. 6E).
Histology
Histology analysis showed a higher amount of blood
vessels per hpf (400) in the AA-MAGs (group A) compared
with plain MAGs (group B) (3.75 0.5 vs. 2.75 0.5, p< 0.05;
Fig. 7A, B, E). These results are in agreement with the anal-
ysis of endothelial cell markers following confocal micros-
copy. In both groups, peripheral angiogenesis was higher.
However, few capillaries could also be detected at the graft’s
core. Ingrowth of vessels was also observed in the periphery
of the acellular negative controls (Fig. 7C, D), but no capil-
laries were detected toward the core. There was no difference
in the number of blood vessels found in the negative control
groups (Fig. 7E).
There was no significant difference in collagen deposition
among groups. The mean collagen deposition score (% of
area covered by collagen of the total cellular reaction) was
mild (0–25%) for both AA-enriched and plain MAGs, as well
as for negative controls (Table 1 and Fig. 7A–D).
Cell infiltration was mild in all groups, with eosinophils
being the most abundant cell type found within the grafts.
Occasional lymphocytes and neutrophils were observed in
all the graft sections (Table 1). Likewise, mild foreign body
reaction was observed in all the groups. Macrophages and
giant cell reaction were observed in all groups. Just one of the
explanted grafts from the negative control (group D) dis-
played moderate necrosis, 26–50% collagen deposition, and
abundant cell infiltration by neutrophils.
Discussion
The main findings in this study are twofold: first, AA
enhances thick bioengineered myocardial tissue survival
in vitro through inhibition of cell apoptosis; second, the
graft’s viability and angiogenic potential in vivo are superior
with AA enrichment. Moreover, we introduced an in vivo
model for myocardial graft prevascularization, which pro-
vides the implanted graft with blood vessels of autologous
origin. We improved graft viability using a biocompatible
and inexpensive compound that could be beneficial for the
tissue engineering and the cell therapy field in general. Stem
cell- and bioartificial tissue-based therapies for the heart re-
main supplementary measures. The unique architecture,
terminal differentiation, and limited regenerative potential of
the heart muscle restrict the capacity of random injections
and implants to restore myocardium efficiently and perma-
nently. The progress of such methods from random and
supplementary to first-line therapeutic options will largely
depend upon improvement on various levels: first, therapies
have to be less traumatic, and second, the effect has to be
stronger and more durable by enhancing graft viability and
functionality in vivo. It is critical to sustain donor cell survival
within bioengineered myocardial grafts through in vitro es-
tablishment of vascular networks for successful cardiac re-
pair. Cell death constitutes a major limitation in cell and
tissue implantation in the frame of restorative therapies.
Some reports indicate that more than 70% of cells die during
the first 2 days after injection into the myocardium,2 whereas
others point out a cell loss of *55% in just 10min following
implantation into the heart.3 Further, there is evidence that,
in spite of capillary formation in vivo, donor cell survival
after myocardial 3D graft implantation is still at risk.19
The addition of AA to the graft constitutes an uncompli-
cated method to counteract fulminant events that occur
during acute ischemia and remodeling within the area of
myocardial lesion. Such events are cytokine and radical
oxygen species liberation, accumulation of purine derivates
(danger signals), inflammation, and apoptosis. AA is a
ubiquitous and essential substance with practically no side-
effects even in high doses and can easily be integrated in a
regenerative therapy protocol. AA participates in a variety of
physiological functions in living organisms. In humans, its
deficiency causes defective healing and disturbed blood vessel
formation because of impaired collagen deposition.12,20 Be-
sides its role in angiogenesis, AA reduces hypoxia-induced
apoptosis in vitro.10,14 Accordingly, we hypothesized that AA
could be used to reduce cell death in myocardial grafts both
in vitro and in vivo.
We used BLI to assess H9C2-Fluc cell survival within thick,
3D MAGs in vitro. The high sensitivity of BLI to monitor
viable cells21,22 was effectively demonstrated in our in vitro
model, as we found a robust correlation between luciferase
activity and histological cell counts. We did not find signif-
icant difference in cell photon emission among groups after
1 day in culture, suggesting homogeneous delivery of cells
within the grafts. However, an increase in cell photon
emission was observed within 5 days in culture, indicating
that cell survival and proliferation were enhanced18 when 3D
myocardial artificial tissues are supplemented with AA. Our
data suggest that AA enhances cell viability within bioen-
gineered tissues in vitro in spite of the harsh conditions in
culture (i.e., static 3D culture, hypoxia, and limited growth
medium volume). Apoptosis is an active process associated
with both the acute and chronic phases of myocardial in-
farction in response to oxidative insults.23 The role of hyp-
oxia on apoptosis via mitochondrial pathway activation of
downstream effector caspases has already been demon-
strated.24 It has been shown that in hypoxic conditions,
hypoxia inhibitor alpha (HIF-1a) promotes apoptosis in
H9C2 cells and cardiomyocytes.10,25,26 There is also evidence
FIG. 3. AA effect on H9C2 cardiomyoblasts’ phenotype in 3D culture. a-Sarcomeric actin staining (red) performed after 3
days in culture in (A) plain MAGs, (B) 5mmol=L AA MAGs, and (C) 50 mmol=L AA; and after 5 days in culture in (D) plain
MAGs, (E) 5mmol=L AA MAGs, and (F) 50 mmol=L AA. Nuclei were counterstained with DAPI (blue). Right-side panels
depict DIC images that were merged to the fluorescence micrographs to identify cell morphology and distribution in the
scaffold. Scale bars indicate 10mm. a-SA, alpha-sarcomeric actin; DIC, differential interference contrast.
‰
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that depletion of AA interrupts HIF-1a proteosomal degra-
dation, leading to increased expression of the latter.12 Our
in vitro experiments showed that graft viability improved via
reduction of cell apoptosis, particularly when medium is
supplemented with both 5 and 50mmol=L AA. Further, the
amount of cells within the AA grafts is preserved over time
in static culture conditions, whereas it significantly decreases
in the plain MAGS. These data correlate to our in vitro BLI
results. Thus, our findings suggest that AA has a protective
effect on donor cells when cultured in thick, 3D bioartificial
constructs. The precise mechanism of such effect was not
explored in this study. However, the enhancement in cell
viability observed in the antioxidant-supplemented groups
could be attributed to AA-driven reactive oxygen species
scavenging, which preserves the integrity of the mitochon-
dria and stabilizes the key regulator of hypoxia (HIF-
FIG. 4. In vivo BLI after 1, 3, and 5 days of graft implantation in the renal pouch. (A) Plain MAGs. (B) AA-enriched MAGs.
(C) The AA-enriched MAGs displayed significantly higher cell photon emission at day 6 after graft implantation (*p< 0.05).
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FIG. 5. Explanted MAGs. Abundant blood vessels infiltrating the (A) plain and (C) AA-enriched MAGs explanted from the
right renal pouch. Fewer blood vessels could be observed by the naked eye in the (B) plain negative (acellular) control and
(D) AA negative (acellular) control, explanted from the left renal pouch. Scale bars indicate 10 mm. Color images available
online at www.liebertonline.com=ten.
FIG. 6. GFP and rat endothelial cell antibody (RECA) expression in explanted MAGs. (A, C) Plain MAGs. (B, D) AA-
enriched MAGs. Confocal micrographs show H9C2-Fluc-GFP cells in green; RECAþ cells in red (blood vessels), and nuclei
stained with DAPI in blue. Vascular networks infiltrating the grafts could be observed in both (A) plain and (B) AA-enriched
MAGs. The amount of GFPþ and RECAþ cells is more evident in the AA group. (C,D) Distribution of donor (GFPþ) cells and
blood vessels in the scaffold. GFPþ cells can be seen in white and nuclei in blue. Asterisks indicate the scaffold structure.
Arrows point to blood vessels. (E) Semiquantitative fluorescence pixel intensity analysis showed that the number of GFP-
positive cells was greater in the AA-enriched MAGs (**p< 0.01). Likewise, expression of RECA was higher in the explanted
grafts from the AA group (*p< 0.05). GFP, green fluorescent protein.
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1a).10,12,25 We do not have direct proof that AA was in its
active form during our study. However, previous stud-
ies have demonstrated that the oxidized form of AA—
dehydroascorbic acid (DHAA)—is neuroprotective in ische-
mia models,27,28 and it also prevents apoptosis and oxidative
damage in macrophages,29 lymphoid, myeloid, and meso-
thelial cells,30 among others.31 DHAA is transported by the
glucose transporters Glut1 into the mitochondria, but not the
reduced form (AA).32 Subsequently, DHHA is reduced back
to AA by protein disulfide isomerases. Thus, we assume that
FIG. 7. Masson’s trichrome staining micrographs of (A) plain MAGs, (B) AA-enriched MAGs, (C) plain negative (acellular)
control, and (E) AA negative (acellular) control. Mild collagen deposition was observed in all groups. Scaffold material is
stained in blue and pointed out with asterisks, to differentiate it from extracellular matrix deposition. Arrows indicate blood
vessels within the grafts. (D) Histological analysis of the explanted MAGs showed fewer amounts of blood vessels per high-
power field (400) in the plain MAGs when compared with the AA-enriched grafts ( p< 0.05). Scale bars indicate 50 mm.
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even if AA was oxidized during our experiments, there was
a protective effect that could have been initiated by DHAA,
which is ultimately reduced back to ascorbate in the mito-
chondria.
Our preliminary in vitro titration studies suggested that
any dosage equal or above 100 mmol=L AA have a cytotoxic
effect on cardiomyoblasts. In vivo, it has been reported that
AA induces apoptosis of myeloid and lymphoid cells at
concentrations above serum level (50 mmol=L).33 The AA
dosages utilized in our in vitro studies have also been pre-
viously reported as safe physiological dosage in other cell
types.10,32 Hence, we chose the lowest possible physiological
dose (5 mmol=L) for our in vivo studies according to this ra-
tionale and the observation that after a 10-fold increase of
AA dose there were no differences in cell survival in vitro.
Besides cytoprotection, AA seems to have an effect on cell
differentiation. It has been shown that 100mmol=L AA en-
hances differentiation of embryonic stem cell into cardio-
myocytes in vitro,34 as well as ex vivo differentiation of adult
bone marrow stem cells into cardiomyocyte-like cells.35 In
our study, immunohistochemical assessment of MAGs after
3 and 5 days in culture revealed that AA induced morpho-
logical myogenic characteristics including elongation and
cell fusion.36 Expression of a-sarcomeric actin was observed
among all groups at day 3, yet more organized z-line-like
patterns were observed in the AA-enriched grafts at both
days 3 and 5 in culture. These results suggest that AA may
have an effect on H9C2 cardiomyoblast differentiation.
However, this interesting observation should be further ad-
dressed in future studies.
To evaluate the AA effect on a bioartificial graft in vivo, we
developed a simple and reproducible renal pouch model. To
assess donor H9C2-Fluc-GFP cell survival within the graft,
we performed noninvasive imaging at days 1, 3, and 6
postimplantation with a bioluminescence charge-coupled
device camera. We observed that 1 week after graft im-
plantation in a renal pouch for in vivo prevascularization,
H9C2 cardiomyoblast survival decreases substantially. The
effect was reflected by reduction of cell photon emission by
nearly 75% of baseline in group B (plain MAGs). This ob-
servation is consistent with previously reported data from
studies where BLI was used to assess myocardial graft sur-
vival in vivo in a heterotopic model of myocardial restoration
in immunosuppressed rats.16 The authors have shown that
H9C2 cardiomyoblasts injected in thin (331mm) gelfoam
grafts undergo massive cell death within 5 days after
implantation into the ischemic myocardium. Early cardio-
myoblast survival within the implanted grafts could only be
improved by addition of collagen and growth factors16 or by
cell transduction with the antiapoptotic hBcl-2 gene.37 In
addition, premature H9C2 cell death has been also docu-
mented after injection in healthy myocardium.38 Here, we
observed that by day 6 postimplantation cell, survival was
significantly enhanced within the implanted myocardial ar-
tificial tissues via AA enrichment (group A). This indicates
donor H9C2-Fluc-GFP cell survival and proliferation in the
host in the AA-enriched MAGs during the first days post-
graft implantation. Yet, confirmation of a proliferative effect
of AA on H9C2 cells needs to be further addressed in future
studies. Our results are of interest for cell transplantation
models, given the fact that we used an allogeneic model in
immunocompetent rats.
A limiting factor on cell or bioartificial tissue engraftment
and survival is immune or inflammatory reaction. In past
works we had demonstrated that the density of equine col-
lagen scaffolds decreases by 30% after 2 weeks of implan-
tation in skeletal muscle and triggers a heavy host cell
infiltration.23 Our previous and current studies also dem-
onstrate a bioluminescence signal drop over the first week,
indicating decrease in cell survival, regardless the adminis-
tration of immunosuppresants (i.e., cyclosporine) or not.12 It
seems that the most sensitive and specific time-window to
capture in vivo photon emission in MAGs—and also the most
accurate—is the first week postimplantation in the renal
pouch. Despite this short time-frame, it was sensitive enough
in our hands to display the difference in bioluminescence
signals in the AA-enriched MAGs. Cell viability after im-
plantation has been demonstrated to be compromised in a
time-dependent manner, even in models where one or two
immunosuppresive agents have been used.12,21 Further, in
our previous study, donor cells were detected using a cell
tracker up to day 21 after graft implantation in im-
munosupressed rats.23 This demonstrates that, in current
models, the fate of grafted tissue is limited by immunologic
barriers even when immunosupression is used.
It is likely that the restorative effect of implanted bioarti-
ficial grafts is achieved via neovascularization=paracrine
effects,6,19 which in turn attenuate infarct expansion, rather
than by cardiomyocyte regeneration, cell differentiation, or
functional graft integration into the host’s myocardium.
Evidence has shown that most bioengineered tissues for
myocardial restoration have mainly focused on multicellular
allogeneic approaches to achieve neovascularization within
bioengineered grafts.8,39–43 With our study, we introduce a
strategy to promote a natural pattern of angiogenic sprout-
ing and graft vascularization in the graft recipient itself.











Cellular reaction (%) 0–25 0–25a 0–25 0–25a
No. of eosinophils=hpf 2.3 0.9 2.0 1.0 1.5 0.0 1.5 0.0
Collagen deposition (%) 0–25 0–25 0–25 0–25
Cellular reaction was defined as the percentage of scaffold area covered by cells, and collagen deposition reflects the percentage of collagen
covered of the total cellular reaction.
aMinimal cellular reaction.
MAGs, myocardial artificial grafts; AA, ascorbic acid; hpf, high-power field.
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A prominent novelty of this study is the introduction of
the pouch model for in vivo graft prevascularization, which
has been proven to be an easy and efficient way to supply
bioengineered myocardial tissues with blood vessels of au-
tologous origin. Using neonatal rat cardiomyocytes cast in an
equine collagen type I mesh, we have recently shown that
graft survival after implantation is determined by host im-
mune responses and degree of angiogenesis.44 In such a
model, vascularization could be seen only in the superficial
layer of the graft after 14–21 days of implantation. Interest-
ingly, the vascular density was significantly lower when the
rats received immunosuppressive therapy.23 Here we pres-
ent a model with superior and faster angiogenic potential.
Moreover, we demonstrate that the neovascularization pro-
cess is enhanced in AA-enriched grafts.
In conclusion, the current model is a powerful one to
vascularize engineered implants in vivo. The possible expla-
nation for the superior AA-enriched graft viability in our
allogeneic model might be both the antiapoptotic and
proangiogenic effects exerted by AA. These findings render
AA a considerable supplement for cell- and tissue transplant-
based therapies. Yet, further studies should be done to
evaluate the effect of AA in 3D bioartificial myocardial grafts
containing human stem cells to confirm the translational
potential of our approach. We are currently carrying out
experiments aiming at postischemic myocardial restoration
using prevascularized AA-enriched MAGs. Our approach
provides a realistic perspective for the clinical setting: en-
hancement of cell survival in 3D bioengineered tissues both
in vitro and in vivo, and a method to mature grafts for later
autologous implantation.
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